Late effects of radioablation: Reiners and colleagues review recent literature on the risk of secondary cancers after radiation treatment and preview an article in this issue of JNM on potential sequelae to radioiodine ablation in children near Chernobyl.
Page 1563
Optimal patient selection for CRT: Ypenburg and colleagues assess whether the extent of myocardial viability on 18F-FDG SPECT at intervention can accurately forecast the success of cardiac resynchronization therapy in patients with heart failure.
Page 1565
Enhanced imaging of granulomas: Nishiyama and colleagues compare tracer uptake on 18F-FDG PET and 67Ga whole-body planar and thoracic imaging in the evaluation of pulmonary and extrapulmonary involvement in patients with sarcoidosis.
Page 1571
Strategic approach to heel pain: Frater and colleagues devise a set of scintigraphic criteria based on blood-pool abnormalities to predict the success of steroid injection therapies in patients with plantar fasciitis.
Page 1577
Noninvasive misery perfusion evaluation: Kobayashi and colleagues describe a novel technique for measuring asymmetric increases in oxygen extraction fraction in H215O PET studies in cerebrovascular disease and point to advantages in technical simplicity and decreased patient discomfort.
Page 1581
Reevaluating 131I doses in the elderly: Tuttle and colleagues look at age-associated differences in maximum tolerated activity in fixed-dose 131I therapy for metastatic thyroid cancer.
Page 1587
PET and bone marrow cellularity: Agool and colleagues investigate the feasibility of using 18F-FLT PET to visualize and quantify proliferative activity in the bone marrow compartment to differentiate among various hematologic disorders.
Page 1592
Identifying somatostatin receptor subtypes: van Essen and colleagues describe the effects of 177Lu-octreotate therapy in patients with metastasized or inoperable paragangliomas, meningiomas, small cell lung carcinomas, and melanomas.
Page 1599
Brain PET and operable NSCLC: Posther and colleagues ask whether 18F-FDG PET provides useful information in patients whose suspected or proven non–small cell lung cancer is considered resectable on the basis of conventional imaging approaches.
Page 1607
Kinetics of 18F-FLT brain imaging: Muzi and colleagues investigate compartmental modeling of tracer transport and retention in 18F-FLT studies to assess cellular proliferation in patients with gliomas.
Page 1612
PET and celiac disease progression: Hadithi and colleagues compare 18F-FDG PET and CT in the detection of enteropathy-associated T-cell lymphoma in patients with refractory celiac disease.
Page 1622
PET/CT vs. CT in thymic tumors: Sung and colleagues assess the utility of 18F-FDG PET/CT in distinguishing subgroups of thymic epithelial tumors and for staging extent of disease.
Page 1628
PET/CT in SNS imaging: Franzius and colleagues evaluate the feasibility of whole-body 11C-HED PET/low-dose CT for examination of tumors of the sympathetic nervous system and compare the results with those from 123I-MIBG scintigraphy and SPECT/CT.
Page 1635
Effective PET/CT dose reduction: Rodríguez-Vigil and colleagues compare contrast-enhanced full-dose PET/CT and unenhanced low-dose 18F-FDG PET/CT in lesion detection and initial staging of Hodgkin's disease and non-Hodgkin's lymphoma.
Page 1643
Novel tracer for prostate imaging: Peng and colleagues investigate the use of 64CuCl2 as a probe in PET localization of human prostate cancer xenografts in mice and discuss the implications for clinical use in locally recurrent tumors.
Page 1649
Radiologic threat preparedness: Barnett and colleagues provide an educational overview of radiologic and nuclear terrorism as public health threats and discuss appropriate preparedness and response perspectives for nuclear medicine professionals.
Page 1653
Optimizing clinical SPECT: Xiao and colleagues compare the performances of Monte Carlo–based and window-based scatter correction in 99mTc SPECT cardiac imaging.
Page 1662
Molecular targeting of mRNA: Watanabe and colleagues investigate the therapeutic effect of Auger electrons emitted by 111In-labeled phosphorothioate antisense oligonucleotides on human neuroblastoma cells.
Page 1670
ImmunoPET investigations: McBride and colleagues continue their work with bispecific antibody pretargeting for tumor imaging, here reporting on a radioiodination procedure to assess PET imaging with 124I.
Page 1678
Tracing dependence: Horti and colleagues evaluate an 11C-labeled analog of a cerebral cannabinoid receptor antagonist as a potential radioligand for PET imaging of addiction and related neuropsychiatric disorders.
Page 1689
Novel serotonin agent: Saigal and colleagues report on the radiosynthesis and in vitro and in vivo binding characteristics of 18F-mefway, a more stable serotonin 5-HT1A agent for use in PET imaging in disorders of the central nervous system.
Page 1697
99mTc-labeled fibronectin antibodies: Berndorff and colleagues detail the synthesis and 99mTc labeling of compounds to target the angiogenesis-associated extracellular matrix protein ED-B fibronectin for scintigraphic molecular imaging of solid tumors.
Page 1707
DNA synthesis imaging: Toyohara and colleagues describe the production of a novel thymidine analog for simplified 11C-PET imaging of DNA synthesis in tumor cell proliferation.
Page 1717
Long-term follow-up recommended: Travis and Stabin review treatment data from children in the Chernobyl area who underwent radioiodine ablation and estimate the increased risk of cancers––including breast cancer––in this population.
Page 1723
ON THE COVER
Because serotonin 5-HT1A receptors have been implicated in disorders of the central nervous system, efforts are under way to develop fluorinated PET radiotracers that are stable to metabolism, easily synthesized, and highly selective for 5-HT1A receptors. 18F-Mefway has shown value as such a radiotracer and is, in addition, sensitive to being displaced by serotonin, suggesting potential as a PET agent for measuring changes in serotonin concentration in the living brain.
SEE PAGE 1703